Origent Receives NIH SBIR Award to Commercialize Predictive Analytics Software to Increase the Efficiency of Human Clinical Trials

Origent Data Sciences has been awarded a Phase 2 Small Business Innovation Research (SBIR) award from the NIH National Center for Advancing Translational Sciences (NCATS). The grant award project, titled “Commercialization of a Software Platform to Increase the Efficiency of Human Clinical Trials using Patient-Level Machine Learning Models” will be performed by Origent in collaboration with researchers at several leading academic medical centers. This project builds on a prototype drug development tool created during Origent’s successful phase 1 SBIR grant using machine-learning generated predictions of patient disease progression. The phase 2 program will commercialize a suite of marketable products designed to answer drug development needs in a portfolio of neurodegenerative diseases. These models and applications will vastly increase the speed and efficiency of drug development in multiple
disease areas, resulting in faster, cheaper, more efficient drug trials that yield numerous new medications to ease human pain and suffering.

This marks Origent’s third NIH SBIR award.  Origent’s Chief Science Officer Dr. David L. Ennist will be the primary investigator for this project. Dr. Jonathan Glass at Emory University will provide support for ALS disease models. Dr. Ray Dorsey and Dr. Charles Venuto at the University of Rochester will support development of models for Parkinson’s disease and Huntington’s disease. Dr. David Bennett of Rush University will provide subject matter expertise in the field of Alzheimer’s disease. Origent will also collaborate closely with a team led by Mr. Alex Sherman at the Neurological Clinical Research Institute at Massachusetts General Hospital, to demonstrate integration of select tools within NCRI’s NeuroBANK PharmaENGINE electronic data capture software.